Endpoints News· @endpts · X·· 4 小时前精选AI 评分78
AI 导读
AbbVie 与 Genmab 的 Epkinly 在一线弥漫性大 B 细胞淋巴瘤（DLBCL）中使进展或死亡风险降低 51%。该结果对罗氏的 Polivy 构成挑战，相关数据由 Endpoints News 报道。
推荐理由
Epkinly 在一线 DLBCL 中降低 51% 进展或死亡风险，读者可据此观察其与罗氏 Polivy 的竞争格局。
正文
AbbVie and Genmab's Epkinly cut the risk of progression or death by 51% in first-line DLBCL, setting up a challenge to Roche's Polivy. https://endpoints.news/abbvie-genmab-trot-out-first-line-dlbcl-win-for-epkinly-in-challenge-to-polivy/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源：Endpoints News · x.com